Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added: 10 months ago Source:  Radcliffe Cardiology
Sleep-disordered breathing (SDB), a condition mediated by intermittent hypoxaemia and autonomic dysregulation, is a well-established contributor to cardiovascular morbidity. A new prospective cohort study suggests that patients with hypertrophic cardiomyopathy (HCM) are particularly at risk, revealing a high prevalence of previously undiagnosed SDB in this population. The research links the… View more

Imaging & Diagnostics

Heart Failure
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
Added: 10 months ago Source:  Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England… View more

Guidelines & Statements

Heart Failure
Acoramidis Efficacy in ATTR-CM Genotypes
Added: 8 months ago Source:  Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small… View more

Inherited and Congenital Cardiac Conditions

Heart Failure
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Added: 10 months ago Source:  Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac… View more

Guidelines & Statements

Heart Failure
Hot Line Sessions Revealed for ESC Congress 2025
Added: 1 year ago Source:  ESC Congress 2025 Scientific Programme
Ten hot line sessions have been announced for ESC Congress 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Hot Line 1Friday 29th August, 11:00am – 12:00pm (CEST)POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian… View more

Intervention

Vascular Disease and Surgery
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Added: 5 months ago Source:  Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments… View more

Heart Failure
Delayed ATTR-CM Diagnosis Common in HF Patients
Added: 5 months ago Source:  Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data… View more

Heart Failure
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly Reduced and Preserved Ejection Fraction
Added: 1 year ago Source:  Radcliffe CKM
A recent study published in Circulation: Heart Failure1 has found that multimorbidity, the presence of two or more chronic health conditions, substantially increases the risk of mortality in patients with heart failure who have mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).The study analyzed data from two major heart failure trials: TOPCAT-Americas (Treatment of Preserved Cardiac… View more

Prevention & Chronic Conditions

Heart Failure
TR in HFpEF: Prognosis Varies by Mechanism
Added: 6 months ago Source:  Radcliffe Cardiology
A new study published in JACC has evaluated the prevalence and prognostic significance of secondary tricuspid regurgitation (STR) across the spectrum of heart failure with preserved ejection fraction (HFpEF), finding that its presence is strongly associated with pulmonary vascular disease (PVD) and that different mechanisms of STR carry distinct prognoses.¹˒²This observational study analysed data… View more

Heart Failure
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Added: 4 months ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,… View more

Cardiovascular Kidney Metabolic

Heart Failure